现代仪器与医疗
現代儀器與醫療
현대의기여의료
Modern Instruments & Mediccal Treatment
2015年
5期
122-124
,共3页
肾细胞癌%鸟嘌呤核苷酸解离抑制因子2%病理
腎細胞癌%鳥嘌呤覈苷痠解離抑製因子2%病理
신세포암%조표령핵감산해리억제인자2%병리
Renal cell carcinoma%Guanine nucleotide dissociation inhibitory factor 2%Pathology
目的：探讨肾细胞癌组织中鸟嘌呤核苷酸解离抑制因子2(RhoGDI2)的表达及其与临床病理因素关系。方法：选择2010年1月至2014年8月期间60例肾细胞癌患者为研究对象；检测癌及癌旁组织 RhoGDI2表达，分析 RhoGDI2的表达与肾细胞癌临床病理关系。结果：肾细胞癌组织中RhoGDI2的表达水平高于癌旁组织，肾细胞癌组织中 RhoGDI2表达的阳性率(70.0%)显著高于癌旁组织(38.3%)，差异有统计学意义（χ2=12.1175,P=0.0005）；肾细胞癌组织中 RhoGDI2的表达与病理分期、分化程度、淋巴结转移、肿瘤大小有显著相关性（P<0.05）。结论：RhoGDI2在肾细胞癌中呈高表达；肾细胞癌中 RhoGDI2的表达参与了肾细胞癌的发病、转移和进展。
目的：探討腎細胞癌組織中鳥嘌呤覈苷痠解離抑製因子2(RhoGDI2)的錶達及其與臨床病理因素關繫。方法：選擇2010年1月至2014年8月期間60例腎細胞癌患者為研究對象；檢測癌及癌徬組織 RhoGDI2錶達，分析 RhoGDI2的錶達與腎細胞癌臨床病理關繫。結果：腎細胞癌組織中RhoGDI2的錶達水平高于癌徬組織，腎細胞癌組織中 RhoGDI2錶達的暘性率(70.0%)顯著高于癌徬組織(38.3%)，差異有統計學意義（χ2=12.1175,P=0.0005）；腎細胞癌組織中 RhoGDI2的錶達與病理分期、分化程度、淋巴結轉移、腫瘤大小有顯著相關性（P<0.05）。結論：RhoGDI2在腎細胞癌中呈高錶達；腎細胞癌中 RhoGDI2的錶達參與瞭腎細胞癌的髮病、轉移和進展。
목적：탐토신세포암조직중조표령핵감산해리억제인자2(RhoGDI2)적표체급기여림상병리인소관계。방법：선택2010년1월지2014년8월기간60례신세포암환자위연구대상；검측암급암방조직 RhoGDI2표체，분석 RhoGDI2적표체여신세포암림상병리관계。결과：신세포암조직중RhoGDI2적표체수평고우암방조직，신세포암조직중 RhoGDI2표체적양성솔(70.0%)현저고우암방조직(38.3%)，차이유통계학의의（χ2=12.1175,P=0.0005）；신세포암조직중 RhoGDI2적표체여병리분기、분화정도、림파결전이、종류대소유현저상관성（P<0.05）。결론：RhoGDI2재신세포암중정고표체；신세포암중 RhoGDI2적표체삼여료신세포암적발병、전이화진전。
Objective: To study expression of guanine nucleotide dissociation inhibitory factor 2 in renal cell carcinoma and the correlation with clinical pathology. Methods: 60 cases of renal cell carcinoma patients were selected as the research object.The expression of RhoGDI2, and the correlation with clinical pathology in renal cell carcinoma were made for statistical analysis. (1)From Jan. 2010 to Aug. 2014, immunohistochemistry was used to assess the expression of RhoGDI2 in 60 pairs of renal cell carcinoma tissues and adjacent pancreatic tissues, and its correlation with clinicopathological features was also analyzed. Results: RhoGDI2 expression level in renal cell carcinoma tissues was higher than the tissue adjacent to carcinoma. Positive rate (70.0%) of RhoGDI2 expression in renal cell carcinoma tissue was significantly higher than tissue adjacent to carcinoma (38.3%), and the difference was statistically significant (χ2=12.1175,P=0.0005). RhoGDI2 expression in renal cell carcinoma tissue were significantly correlated with pathological staging, degree of differentiation, lymph node metastasis, tumor size (P<0.05). Conclusion: RhoGDI2 is highly expressed in renal cell carcinoma; The expression of RhoGDI2 is involved in the pathogenesis of renal cell carcinoma, metastasis and progress in renal cell carcinoma.
